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Background: Acute lower respiratory tract infection is the commonest disease affecting children under five worldwide.
Respiratory syncytial virus (RSV) is among the most common causative pathogens. Epidemiological data suggest
an association between severe viral respiratory infections in infancy and increased incidence of childhood wheeze
and asthma. DNA methylation is involved in immune cell differentiation and identity. It provides an avenue for
environmental influences on the genome and therefore has potential as a marker for sustained effects of infectious
insults. In this study we investigated the association between DNA methylation patterns in the perforin gene (PRF1) in
childhood and a history of hospitalisation for severe RSV disease in the first two years of life.
Methods: In this retrospective study, we explored patterns of whole blood DNA methylation at a methylation sensitive
region of the proximal PRF1 enhancer in a group of children with a record of hospitalisation for severe RSV disease
during infancy (n = 43) compared to healthy controls matched for age and sex with no similar hospitalisation history,
no allergy and no persistent wheeze (n = 43). Univariate and bivariate conditional logistic regression analyses were
conducted to test the association between PRF1 enhancer methylation and record of hospitalisation for RSV disease.
Results: Children with a record of hospitalisation for severe RSV bronchiolitis demonstrated markedly lower levels of
DNA methylation at two cytosine-phosphate-guanine dinucleotide (CpG) loci of the PRF1 proximal enhancer,
corresponding to a signal transducer and activator of transcription 5 (STAT5) responsive element, compared to
controls, adjusted odds ratios of 0.82 (95% confidence interval [CI] 0.71, 0.94) and 0.73 (95% CI 0.58, 0.92) for each
1% increase in DNA methylation. Smoking in the household showed a significant influence on DNA methylation
at the assayed positions.
Conclusions: Our findings support an association between childhood DNA methylation patterns in PRF1 and a
record of severe RSV infection in infancy. Longitudinal studies are required to establish the utility of PRF1 methylation
as a marker of severe RSV disease.
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Acute lower respiratory tract infection (LRTI) is the lead-
ing cause of child mortality worldwide, the greater burden
falling on developing countries [1]. On a global scale,
respiratory syncytial virus (RSV) is the most common
causative pathogen of LRTI in children under five years
old and a major cause of hospital admission particularly
in the first year of life. The incidence in infants is three
times higher than overall incidence in children under
five years of age [2].
Evidence is strong that viral respiratory infections in
infancy are associated with increased risk of childhood
wheezing, atopy and asthma [3], up to adolescence [4]
and possibly early adulthood [5]. It is not entirely clear
whether viral LRTIs including RSV are indeed a causal fac-
tor or simply indicate heightened susceptibility to asthma
although considerable evidence supports a causal link [6].
DNA methylation, the commonest epigenetic alteration
known to date, is crucial to processes of cellular differenti-
ation and the establishment of cellular identity [7]. In con-
trast to genetic hardwire, genome-wide patterns of DNA
methylation and other chromatin modifications do not
persist throughout life but undergo specific changes at de-
fined stages of development that contribute to lineage and
tissue-specific gene expression [8]. As such, epigenetic
modifications constitute a dynamic interface between gen-
ome and environment. Epigenetic modifications have been
characterized in key effector and regulator genes as deter-
minants of cell type and function in the immune system
and modulators of immune response [9].
Epigenetic dysregulation is one potential mechanism
which may mediate between adverse in utero and early
life exposures such as severe infections and immunological
functions in later life [10]. The interactions mediating the
relationship between severe RSV bronchiolitis and adverse
consequences in childhood are broadly understood to
be immunological in nature [11] but are yet to be fully
uncovered. Perforin is a potent cytolytic molecule of
cytotoxic T cells and natural killer (NK) cells capable of
non-specific lysis of virus-infected cells [12]. Perforin
expression is under the control of interleukin (IL)-2,
signalling through signal transducer and activator of
transcription (STAT)-5 [13].
We previously reported higher methylation of specific
cytosine-phosphate-guanine dinucleotide (CpG) positions
corresponding to a STAT5 binding element in an enhan-
cer region of PRF1 in cord blood DNA of infants who sub-
sequently developed frequent LRTI during their first
year of life [14]. Considering the role perforin plays in
the cellular immune response to virus infections, we
hypothesised that severe RSV infection in infancy might
be associated with alterations in PRF1 methylation. Ac-
cordingly, we assayed DNA methylation at the two
CpGs of the STAT5 element in the PRF1 enhancer, in acohort of children with a history of severe RSV bronchio-
litis requiring hospitalisation during infancy compared to
healthy children matched by sex and age at blood collec-
tion with no record of severe bronchiolitis, allergic disease
or persistent wheeze.Methods
Study subjects
Children with history of severe RSV disease were drawn
from a cohort of children recruited at the University
Children’s Hospital and St Josef ’s Community Children
Hospital in Freiburg, Germany, between September 1998
and March 2005 for the primary purpose of investigating
genetic associations with severe RSV disease [15].
All children who were hospitalised for severe RSV dis-
ease in the first two years of life were considered eligible
for inclusion in the cohort. Cases had symptoms of bron-
chiolitis at admission, such as wheezing and tachypnoea,
and needed either supplementary oxygen and/or gavage
feeding and/or intravenous fluids. Infection with RSV was
confirmed by antigen test and/or polymerase chain reac-
tion (PCR). Parents of all eligible patients were approached
to enrol in the study and included upon informed consent.
Children with congenital heart defects, immunodefi-
ciency, or chromosomal aberrations were excluded from
the study. Information on treatment course was obtained
from patients’ hospital records regarding requirement
for corticosteroid, antibiotic and oxygen therapy as well
as a record of persistent wheeze. Indicators of family envir-
onment such as number of siblings and parents smoking
in the house were obtained via standardized questionnaire
filled in by the parents at time of blood draw. Blood sam-
ples were collected from study participants at a median of
3.25 years after hospitalisation (IQR 3.16–4.00). From a
total baseline study population of 208 cases blood samples
were obtained from 131 cases.
Healthy controls matched to cases by sex and approxi-
mate ages were recruited from healthy children seen at
several paediatric practices in the same catchment area
of Freiburg in southwestern Germany. Controls were re-
cruited in the same time period as cases, 1998 to 2005,
for the original purpose of the genetic association studies
mentioned. Controls had no record of severe bronchiolitis
in the first two years of life and were never diagnosed with
persistent wheeze or allergic disease. Sex and age match-
ing was not considered at time of recruitment but was
undertaken for the purpose of this study. Controls were
matched 1:1 on sex and the same age at blood sampling
(plus or minus one year).
Blood samples were collected in ethylenediaminetetra-
acetic acid (EDTA) tubes processed, aliquoted and stored
at −20 °C. Methylation assays were performed on genomic
DNA derived from peripheral blood leukocyte samples of
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healthy children with no history of severe RSV disease.
Collection of samples and study protocols were ap-
proved by the Ethics Commission of the Medical Centre,
University of Freiburg. Written informed consent was
obtained from parents of all participating children.
DNA extraction and bisulfite modification
Genomic DNA was manually extracted from peripheral
blood leukocytes using the QIAamp® DNA Blood Midi
Kit (Qiagen GmbH, Hilden, Germany) according to the
manufacturer’s protocol. DNA was stored at −20 °C before
use. In preparation for pyrosequencing, 500 ng of
DNA was bisulfite converted using the EZ DNA
Methylation-Gold™ Kit (Zymo Research Corp, Irvine,
CA, USA) according to the manufacturer’s protocol.
Non-methylated cytosines in this procedure are converted
to uracil which is replaced in subsequent amplification
by thymine while methylated cytosines are preserved
unchanged.
Target cytosine dinucleotides
Cytosine methylation levels were measured in two CpG
dinucleotides in the methylation sensitive region (MSR)
of PRF1 located 929 to 577 base pairs (bp) upstream of
the transcription start site (TSS) and referred to as CpGs
E1 and E2 as detailed previously [14]. Figure 1 shows the
two CpGs investigated in the MSR of the PRF1 proximal
enhancer.
Bisulfite pyrosequencing
Quantification of cytosine percent methylation was per-
formed by pyrosequencing of bilsulfite-converted DNA.
Primers were designed with the PyroMark Assay Design
Software v.2.0.1.15 (Qiagen GmbH, Hilden, Germany) to
amplify the target region and purchased from Apara
Biosciences GmbH (Denzlingen, Germany). Each assay
included non-CpG cytosines as internal controls to ver-
ify efficient bisulfite conversion.
1.5 pmol each of the forward primer 5′-GAGTGGGA
GAAGAGAGATG-3′ and the reverse biotinylated primer
5′-CCCCCAATACCCTATAAATCACTC-3′ were used to
amplify the fragment of interest, sized 256 base pairs (bp),
from an input amount of 0.5 μl bisulfite-converted DNA,Fig. 1 The proximal PRF1 enhancer and binding sites for transcription
factors. Individual CpGs marked by diamond shapes. Assayed CpGs
identified as E 1 and 2. CRE: cAMP responsive element; AP2: activating
protein 2; STAT5: signal transducer and activator of transcription [14]25 ng assuming complete recovery from bisulfite conver-
sion, in a final reaction volume of 12.5 μl using the Pyro-
Mark PCR Kit (Qiagen GmbH, Hilden, Germany). PCR
conditions were as follows 95 °C for 10 min; 50 cycles of
94 °C for 30 s, annealing for 30s, 72 °C for 30 s; and a final
extension step at 72 °C for 10 min.
PCR products were rendered single stranded according
to established protocol [16]. 3 pmol of the sequencing
primer 5′-GTGAGGATAGTTAGTGG-3′ were used to
perform the pyrosequencing reaction on the PyroMark
Q96 MD apparatus (Qiagen GmbH, Hilden, Germany).
The percentage methylation at each CpG was calculated
using the PyroMark CpG Software v.1.0.11 build 14
(Qiagen GmbH, Hilden, Germany). The quantitative per-
formance of the pyrosequencing assay was assessed by
measuring methylation standards of known proportions
of unmethylated (whole genome amplified) and fully
methylated (Sss-I treated) genomic DNA and optimized
by means of an annealing temperature gradient. Matched
cases and controls were consistently assayed in the same
batch. All samples were assayed in duplicates and the
mean percentage of the two measurements calculated and
used for statistical analyses.Statistical analysis
Univariate analyses were conducted on each candidate
gene locus to assess methylation results for normality
and identify potential outliers. Methylation measurements
greater than 3 standard deviations from the mean were
considered as potential outliers. To identify potential con-
founding factors not accounted for by matching, age at
sampling, gestational age (<37 weeks or ≥37 weeks), house-
hold smoking (yes or no), and whether or not the child
had a sibling under 5 years of age (yes or no) were assessed
for association with RSV case status and methylation levels
using non-parametric testing methods (Chi-square, Fisher’s
exact, Spearman’s coefficients and Kruskall-Wallis tests).
Selection of potential confounders was based on a
p-value ≤ 0.05. Household smoking was associated with
both RSV case status and methylation levels and thus
considered a potential confounding factor for adjust-
ment in logistic regression models. Bivariate and ad-
justed conditional logistic regression models were used
to calculate the odds ratio (OR) per 1% difference in
methylation, 95% confidence interval (CI), and p-value
for the association with case status at each candidate
gene locus after adjustment for age at blood sampling
and household smoking. In order to determine the ef-
fect of potential outliers on the results, a second bivari-
ate analysis was performed restricted to pairs (case and
matched control) containing no outlier values. All statis-
tical analyses were performed using SAS 9.3 for Windows
(SAS Institute, Cary, US).
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Study population
RSV cases and controls (n = 86) were 1:1 matched accord-
ing to sex and approximate age at time of blood draw.
Features of the RSV case-control population are presented
in Table 1. Overall, children were predominantly male
(65%). RSV cases had a median age of 3.3 years (interquar-
tile range [IQR] 3.2, 4) while controls had a median age of
4 years (IQR 4.0, 5.0). The majority of children were born
term, 81.1% of cases and 87.5% of controls. Cases had
more often siblings and were more exposed to household
smoking compared to controls (Table 1).
Among the cases 70% had a complicating bacterial in-
fection requiring antibiotic medication, 30% received
corticosteroid therapy and 10% already had a persistent
wheeze before hospitalisation for RSV infection. Hospi-
talisation for severe RSV disease was associated with ex-
posure to smoking in the household (p = 0.02) and
having one or more siblings (p = 0.02).
Differential DNA methylation at the PRF1 enhancer
Among all subjects, exposure to smoking in the house-
hold was associated with lower DNA methylation levels
at E1 and E2 (p = 0.003, 0.004) but no associations were
observed for gestational age, sex, or sibling status.
Among RSV cases only (for whom more robust data was
available), a diagnosis of persistent wheeze prior to hospi-
talisation for RSV disease was associated with lower DNA
methylation levels in E1 (p = 0.04). None of the other
clinical characteristics explored showed a statistically
significant association with DNA methylation at the
PRF1 loci except maternal asthma (p = 0.04 with E2)
(Table 2). When cases and controls were combined, ex-
posure to smoking in the household was associated withTable 1 Characteristics of children with history of hospitalisation for
RSV-cases
n % or median (p25, p





≥37 weeks 30 81.1%







*p-value calculated as either chi-square, Fisher’s exact, or Kruskal-Wallis testlower DNA methylation levels at E1 and E2 (p = 0.003,
0.004) but no associations for gestational age, sex, and
sibling status remained non-significant (Table 3).
Median DNA methylation levels of 69.5% (IQR 62.5,
74.5) and 65.0% (IQR 62.0, 70.0) were observed at CpGs
E1 and E2 (illustrated in Fig. 1) in children hospitalised
for RSV disease compared to 79.0% (IQR 75.0, 84.0) and
75.0% (IQR 72.0, 79.0) in controls (p < 0.001). Logistic
regression analysis adjusted for exposure to smoking in
the household demonstrated OR of 0.82 (95% CI 0.71,
0.94) and 0.73 (95% CI 0.58, 0.92) for E1 and E2 respect-
ively for each 1% increase in methylation in association
with case status (Table 4).
In an additional sensitivity analysis, adjustment for age
at blood draw was performed to account for the loose age
matching between cases and controls. Adjustment for age
at blood sampling alone did not alter the point estimates.
The small sample size however did not allow adjustment
for both household smoking exposure and age at blood
sampling.Discussion
We investigated the whole blood DNA methylation pat-
tern of two CpG sites in the proximal enhancer of the
immune effector gene PRF1 in a group of children with
a history of hospitalisation for RSV disease in infancy
compared to healthy children of matched sex and approxi-
mate age at blood sampling. In cases with RSV history we
found markedly lower levels of DNA methylation at two
loci of the PRF1 proximal enhancer. In addition, infants
who were admitted for RSV disease were predominantly
male, had one sibling or more, and were more likely to
come from a household where an adult smoked.RSV bronchiolitis and healthy controls
Controls p-value*
75) n % or median (p25, p75)













Table 2 Differential PRF1 enhancer methylation according to clinical features of RSV bronchiolitis among cases only
Characteristics DNA methylation levels at the PRF1 enhancer
CpG E1 CpG E2
n median (p25, p75) or
Spearman’s coefficient
p-value* n median (p25, p75) or
Spearman’s coefficient
p-value*
Age at hospitalisation (years) 38 −014 0.42 38 −016 0.33
Age at blood sampling 43 0.08 0.61 43 0.10 0.54
Gender 0.79 0.30
Female 15 68.0 (62.5, 73.5) 15 67.0 (63.0, 70.0)
Male 28 69.5 (61.0, 74.5) 28 64.8 (59.3, 70.0)
Gestational age 0.32 0.98
≥37 weeks 30 68.3 (63.0, 73.5) 30 64.8 (62.0, 68.5)
<37 weeks 7 62.0 (36.0, 73.5) 7 65.5 (36.0, 72.0)
Sibling status 0.62 0.57
None 2 55.3 (36.0, 74.5) 2 53.0 36.0, 70.0)
≥1 33 69.5 (63.0, 74.5) 33 65.5 (63.0, 71.5)
Smoking in the household 0.08 0.14
No 19 72.0 (66.0, 74.0) 19 67.0 (63.5, 72.0)
Yes 21 65.5 (61.0, 70.0) 21 64.0 (61.5, 68.5)
Previous wheeze 0.04 0.13
No 36 69.5 (63.8, 74.5) 36 65.5 (62.5, 71.0)
Yes 4 62.3 (43.5, 64.3) 4 63.3 (42.0, 64.5)
Parent allergic disease 0.50 0.23
No 20 69.5 (63.0, 75.0) 20 67.0 (63.5, 71.8)
Yes 20 68.8 (62.3, 72.8) 20 64.0 (61.8, 69.3)
Paternal asthma 0.07 0.19
No 37 69.5 (63.0, 74.5) 37 65.0 (63.0, 70.5)
Yes 3 62.0 (25.0, 66.0) 3 63.5 (21.0, 65.5)
Maternal asthma 0.32 0.04
No 37 69.5 (63.0, 74.5) 37 65.5 (63.0, 70.5)
Yes 3 66.0 (25.0, 70.0) 3 61.5 (21.0, 63.5)
Days of oxygen supplementation 40 −0.05 0.74 40 −0.11 0.51
Antibiotic therapy 0.62 0.65
No 12 69.5 (46.8, 74.5) 12 65.0 (46.5, 71.8)
Yes 28 69.5 (63.8, 74.0) 28 65.0 (63.5, 69.5)
Corticosteroid therapy 0.38 0.32
No 28 67.8 (61.8, 74.0) 28 64.8 (61.5, 70.3)
Yes 12 71.3 (65.0, 74.0) 12 66.5 (64.0, 71.0)
Differences in the total number of observations are due to missing data
n number of observations, p25 25th percentile, p75 75th percentile
*p-value for categorical variables calculated using Kruskal-Wallis test
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ation of male sex with severe RSV infection in the first
three months of life in the Tucson Children’s Respiratory
Study [17], an association confirmed in multiple other
studies [18]. Having a sibling has been repeatedly re-
ported as a risk factor for RSV induced LRTI in infancy
[19]. The association with passive exposure to cigarettesmoke is less consistent [18] but appears strong in com-
bination with prematurity [20]. Infants exposed to post-
natal maternal smoking suffer a more severe course of
RSV disease with lower oxygen saturation during hospi-
talisation than the non-exposed [21]. In a large-scale
surveillance of US children under five years spanning
four years Hall and co-workers identified only age under
Table 3 Differential PRF1 enhancer methylation according to characteristics of RSV bronchiolitis among all subjects (cases and
controls combined)
Characteristics DNA methylation levels at the PRF1 enhancer
CpG E1 CpG E2
n median (p25, p75) p-value* n median (p25, p75) p-value*
Gender 0.06 0.09
Female 30 74.8 (66.0, 83.0) 30 73.3 (67.0, 78.5)
Male 56 74.0 (60.0, 78.8) 56 70.8 (64.3, 74.5)
Gestational age 0.26 0.61
≥37 weeks 58 74.5 (67.5, 80.0) 58 70.8 (64.0, 75.0)
<37 weeks 11 73.5 (55, 75.5) 11 70.0 (55.0, 73.5)
Sibling status 0.34 0.25
None 11 75.5 (74.5, 84.5) 11 73.0 (70.0, 78.5)
≥1 55 74.5 (66.0, 80.0) 55 71.5 (64.0, 75.0)
Smoking in the household 0.003 0.004
No 43 75.5 (70.0, 83.2) 43 72.0 (67.0, 78.5)
Yes 29 69.5 (62.5, 76.0) 29 68.0 (63.0, 72.5)
Differences in the total number of observations are due to missing data
n number of observations, p25 25th percentile, p75 75th percentile
*p-value calculated using Kruskal-Wallis test
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risk factors for RSV hospitalisation [22]. The discrepancy
may be related to the wider age definition in the latter
study.
From the variables available for this analysis only expos-
ure to smoking in the household showed an association
with DNA methylation at the PRF1 enhancer. Smoking is
a potent environmental modulator of genome-wide DNA
methylation including in utero, when methylation patterns
are analysed in cord blood [23]. The association we ob-
served between reduced DNA methylation at the PRF1
enhancer in whole blood three to four years after hospital-
isation for severe RSV disease during infancy remained
significant after adjustment for smoking exposure. A sep-
arate analysis adjusted for age was performed to address
the loose age matching in the study population but
showed no significant difference in estimates.
The two CpGs assayed are located in a segment of the
PRF1 enhancer characterised as a methylation sensitiveTable 4 Crude and adjusted model results for association






Odds Ratio (95% CI)† p-value Odds Ratio (95% CI)† p-value
E1 0.81 (0.71, 0.92) <0.001 0.82 (0.71, 0.94) 0.010
E2 0.67 (0.52, 0.87) 0.003 0.73 (0.58, 0.92) 0.009
aadjusted for household smoking
†Odds ratio for risk of case status based on a 1% increase in PRF1 methylation
level and case statussegment. Methylation of the PRF1 MSR results in sup-
pression of PRF1 while demethylation is associated
with heightened expression in T cells [24]. Our analysis
was performed on DNA derived from whole blood,
and we cannot with the available measurements rule
out a confounding effect of cell subtype composition
on our measurements. Hence, our results might reflect
an expansion of the perforin-positive lymphocyte
population rather than a true demethylation event in
otherwise PRF1-methylated cells or more likely a com-
bination of both. Perforin is normally expressed in al-
most all NK cells, NKT cells, γα T cells and around
20–30% of cytotoxic T cells and is broadly considered
a marker of effector CD8+ T cell activation [25].
CD8+ T cell proliferation and differentiation from naïve
to effector and memory T cells in response to virus infec-
tion is associated with distinct epigenetic profiles corre-
sponding to cell-specific transcriptional programmes [26].
We previously reported a prospective association between
increased methylation at the PRF1 enhancer MSR in
cord blood and LRTI in the first year of life suggesting
a reduced T cell/perforin reaction [14]. A robust cell-
mediated cytotoxic response is necessary for viral clear-
ance of RSV infection [27] but failure to effectively
regulate this reaction might contribute to T cell medi-
ated lung injury [28].
Accordingly, the reduced DNA methylation we observe
in this retrospective study in contrast to the increased
DNA methylation at the same locus in our prospective
study of cord blood PRF1 methylation and LRTI risk
in the first year of life might reflect the differing
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situations. A robust cytotoxic response is needed to pro-
tect against respiratory viral infection, and reduced PRF1
expression in newborns as indicated by higher DNA
methylation is associated with increased risk of LRTI. On
the other hand, increased expression of PRF1 as indicated
by reduction in DNA methylation, is associated with a rec-
ord of severe RSV infection, and might contribute to lung
damage. For instance, Arnold et al. reported an increase in
perforin-positive peripheral blood lymphocytes in both in-
trinsic and allergic asthma [29].
Within the group of children with a history of RSV
hospitalisation, we observed a greater reduction of whole
blood DNA methylation at the PRF1 enhancer in a sub-
group who had a persistent wheeze before hospitalisation.
Accordingly, we assayed the same locus in a separate
group of asthmatic children and could observe intermedi-
ate levels of DNA methylation when compared to the
higher levels in controls and lower levels in children with
a history of hospitalisation for RSV disease (data not
shown). Our analysis of asthmatic children (6 years old) is
hampered by the lack of exact age-matched healthy con-
trols which may have resulted in spurious results.
The cross-sectional design of this study does not allow
for conclusions regarding temporal changes in DNA
methylation. Only a longitudinal analysis would establish
whether the reduced DNA methylation levels we observed
are restored as the affected children grow. Therefore, fur-
ther research may be warranted to establish causality.
Childhood is a period of intense age-related changes in
peripheral blood DNA methylation with a three to four-
fold higher rate of change compared to adulthood [30].
Recurrent wheezing is a common complication of se-
vere RSV bronchiolitis in infancy Meta-analysis of lon-
gitudinal studies however suggests that the heightened
risk of wheeze and/or asthma is abolished by the fifth
year of follow up [31]. DNA methylation is discussed as
a mechanism of gene-environment interplay in the patho-
genesis of asthma [32]. Several candidate gene and genome-
wide association studies have so far documented differential
DNA methylation patterns in asthma patients, including in
Tcells [33] and airway epithelial cells [34].
When looking at the results, the following limitations
should be considered: Due to difficulty in obtaining a
larger number of sex and age matched controls our
study consisted of only 86 subjects. We had only limited
additional data on our subjects to test for potential con-
founding. Though we were able to rule out confounding
by two important factors previously associated with severe
RSV infection (presence of smoking in the household and
additional siblings in the household), the limited sample
size did not allow for a thorough investigation of potential
confounders. We could not completely rule out the possi-
bility that the association we observed was due to chanceselection of discordant subjects. Finally, due to the retro-
spective nature of the case-control design and measure-
ment of only blood DNA methylation at one point in
time, it remains unclear whether methylation levels were
affected already prior to RSV infection. To further explore
our preliminary findings a longitudinal analysis of a larger
cohort with the possibility of isolating lymphocyte sub-
types backed by sufficient epidemiological exposure data
would be required.
Conclusions
We observed a reduction in blood DNA methylation of
the PRF1 proximal enhancer in children in association
with previous hospitalisation for severe RSV bronchiolitis
during infancy. This pattern of differential DNA methy-
lation is worthy of investigation as a candidate marker
for complications of severe RSV infection particularly
persistent wheeze and childhood asthma. Our findings
underscore the importance of considering the temporal
dimension when studying DNA methylation patterns.
Furthermore, they highlight the need for well-matched
adequately powered longitudinal studies of epigenome-
wide DNA methylation which, when supplemented with
further epidemiological data, may improve our under-
standing of the dynamics of gene-environment interaction
in the pathogenesis of disease.
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